Emicizumab in Acquired Hemophilia A

Condition:   Adult Patients (>= 18 Years) Diagnosed With Acquired Hemophilia A (AHA) Based on a Reduced FVIII Activity and a Positive Nijmegen Bethesda Inhibitor Titer Intervention:   Drug: Emicizumab Injection Sponsors:   GWT-TUD GmbH;   Hoffmann-La Roche;   Hannover Medical School Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials